×

Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof

  • US 20050130230A1
  • Filed: 01/29/2005
  • Published: 06/16/2005
  • Est. Priority Date: 09/23/2003
  • Status: Active Grant
First Claim
Patent Images

1. A method of determining presence or risk of hemorrhage in a human subject, said method comprising:

  • obtaining a test sample from a human subject;

    analyzing the obtained test sample for the presence or amount of (1) cellular fibronectin and (2) one or more additional markers both proteomic and non-proteomic for, or mass spectrometry peak levels of, any of apoptosis, cellular adhesion, cellular injury, coagulation, glial activation, inflammatory mediation, myelin breakdown, thrombosis, vascular damage, and specific and non-specific markers of cerebral injury; and

    correlating (1) the presence or amount of said cellular fibronectin and said or more additional markers or peak levels, and (2) clinical patient information, other than the cellular fibronectin and additional makers or peak levels, for cerebral injury, in order to deduce a probability of present or future risk of a hemorrhage for the subject.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×